Imigran Radis

Sumatriptan, the active ingredient in Imigran Radis, is a Triptan presented as an oral tablet for the acute treatment of migraine attacks with or without aura in adults. Approved in the European Union, it targets specific serotonin receptors to produce rapid relief of headache pain, nausea and photophobia.

GNH USA supplies Imigran Radis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare providers worldwide.

Sumatriptan is a Triptan indicated for the acute management of migraine.

Migraine with aura: provides rapid relief of headache, nausea, photophobia and phonophobia. Migraine without aura: reduces pain intensity and associated symptoms within hours. Acute migraine in adults: enables patients to achieve pain freedom when taken at the first sign of an attack.

Common Side Effects: - Chest tightness or pressure - Tingling or numbness in fingers or face - Warmth or flushing sensation - Dizziness or light‑headedness - Nausea or abdominal discomfort - Fatigue or drowsiness

Serious or Rare Side Effects: - Coronary vasospasm or myocardial ischemia - Serotonin syndrome, especially with other serotonergic drugs - Severe allergic reaction (anaphylaxis, angioedema) - Hypertension or hypertensive crisis - Cardiac arrhythmias - Stroke or transient ischemic attack

Before initiating therapy, evaluate cardiovascular risk and contraindications.

Assess cardiovascular risk: confirm no history of ischemic heart disease or uncontrolled hypertension. Avoid use with MAO inhibitors: discontinue MAO‑I therapy at least 14 days prior. Caution in patients with uncontrolled hypertension: monitor blood pressure closely. Do not exceed recommended dose frequency: follow prescriber guidance on maximum doses per 24 hours. Monitor for signs of serotonin syndrome: educate patients about symptoms. Store at below 25°C: keep in the original pack, protect from moisture and light.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - Other triptans or ergot derivatives: risk of severe vasospasm.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or other serotonergic agents: monitor for serotonin excess. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sumatriptan plasma levels. - Antihypertensive agents (beta‑blockers, calcium channel blockers): may enhance vasoconstrictive effects.